{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:05:02Z","timestamp":1769821502960,"version":"3.49.0"},"reference-count":83,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CNDI-UEFISCDI","award":["PN-III-P1-1.1-PD-2019-0574, no. 179\/2020"],"award-info":[{"award-number":["PN-III-P1-1.1-PD-2019-0574, no. 179\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Chronic pain determines a substantial burden on individuals, employers, healthcare systems, and society. Most of the affected patients report dissatisfaction with currently available treatments. There are only a few and poor therapeutic options\u2014some therapeutic agents are an outgrowth of drugs targeting acute pain, while others have several serious side effects. One of the primary degradative enzymes for endocannabinoids, fatty acid amide hydrolase (FAAH) attracted attention as a significant molecular target for developing new therapies for neuropsychiatric and neurological diseases, including chronic pain. Using chemical graph mining, quantitative structure\u2013activity relationship (QSAR) modeling, and molecular docking techniques we developed a multi-step screening protocol to identify repurposable drugs as FAAH inhibitors. After screening the DrugBank database using our protocol, 273 structures were selected, with five already approved drugs, montelukast, repaglinide, revefenacin, raloxifene, and buclizine emerging as the most promising repurposable agents for treating chronic pain. Molecular docking studies indicated that the selected compounds interact with the enzyme mostly non-covalently (except for revefenacin) through shape complementarity to the large substrate-binding pocket in the active site. A molecular dynamics simulation was employed for montelukast and revealed stable interactions with the enzyme. The biological activity of the selected compounds should be further confirmed by employing in vitro and in vivo studies.<\/jats:p>","DOI":"10.3390\/ph15010038","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T06:55:03Z","timestamp":1640674503000},"page":"38","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Identifying FAAH Inhibitors as New Therapeutic Options for the Treatment of Chronic Pain through Drug Repurposing"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7658-5082","authenticated-orcid":false,"given":"Anca","family":"Zanfirescu","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-3069","authenticated-orcid":false,"given":"Georgiana","family":"Nitulescu","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2880-9381","authenticated-orcid":false,"given":"Dragos Paul","family":"Mihai","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-8052","authenticated-orcid":false,"given":"George Mihai","family":"Nitulescu","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1017\/S0029665113003650","article-title":"Endocannabinoid system and pain: An introduction","volume":"73","author":"Burston","year":"2014","journal-title":"Proc. Nutr. Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s11481-012-9351-6","article-title":"The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55","volume":"7","author":"Sharir","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Iannotti, F.A., and Vitale, R.M. (2021). The endocannabinoid system and PPARs: Focus on their signalling crosstalk, action and transcriptional regulation. Cells, 10.","DOI":"10.3390\/cells10030586"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Li, Y., Chen, X., Nie, Y., Tian, Y., Xiao, X., and Yang, F. (2021). Endocannabinoid activation of the TRPV1 ion channel is distinct from activation by capsaicin. J. Biol. Chem., 297.","DOI":"10.1016\/j.jbc.2021.101022"},{"key":"ref_5","first-page":"e10436","article-title":"Cannabinoid receptors and their relationship with chronic pain: A narrative review","volume":"12","author":"Anthony","year":"2020","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"110163","DOI":"10.1016\/j.pnpbp.2020.110163","article-title":"CB1 allosteric modulators and their therapeutic potential in CNS disorders","volume":"106","author":"Mielnik","year":"2021","journal-title":"Prog. Neuro. Psychopharmacol. Biol. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Murphy, T., and Le Foll, B. (2020). Targeting the endocannabinoid CB1 receptor to treat body weight disorders: A preclinical and clinical review of the therapeutic potential of past and present CB1 drugs. Biomolecules, 10.","DOI":"10.3390\/biom10060855"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-pharmtox-030220-112741","article-title":"Targeting endocannabinoid signaling: FAAH and MAG lipase inhibitors","volume":"61","author":"Straub","year":"2021","journal-title":"Ann. Rev. Pharmacol. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zanfirescu, A., Ungurianu, A., Mihai, D.P., Radulescu, D., and Nitulescu, G.M. (2021). Targeting monoacylglycerol lipase in pursuit of therapies for neurological and neurodegenerative diseases. Molecules, 26.","DOI":"10.3390\/molecules26185668"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbr.2018.06.030","article-title":"FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats","volume":"353","author":"Flannery","year":"2018","journal-title":"Behav. Brain Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"111953","DOI":"10.1016\/j.ejmech.2019.111953","article-title":"A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents","volume":"188","author":"Tripathi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-008-9075-y","article-title":"Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation","volume":"11","author":"Schlosburg","year":"2009","journal-title":"AAPS J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1472-8206.2006.00442.x","article-title":"The cannabinoid system and its pharmacological manipulation\u2014A review, with emphasis upon the uptake and hydrolysis of anandamide","volume":"20","author":"Fowler","year":"2006","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neulet.2018.11.045","article-title":"Animal models of congenital hypoalgesia: Untapped potential for assessing pain-related plasticity","volume":"702","author":"Monteiro","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.bja.2019.02.019","article-title":"Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity","volume":"123","author":"Habib","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/cmdc.200900120","article-title":"Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: Chemical and biological stability","volume":"4","author":"Vacondio","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1021\/jm701631z","article-title":"Synthesis and quantitative structure\u2212activity relationship of fatty acid amide hydrolase inhibitors: Modulation at the N-portion of biphenyl-3-yl alkylcarbamates","volume":"51","author":"Mor","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1016\/j.bmcl.2011.06.096","article-title":"The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH)","volume":"21","author":"Otrubova","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1021\/jm800311k","article-title":"Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors","volume":"51","author":"Seierstad","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejmech.2014.09.037","article-title":"Computational insights into function and inhibition of fatty acid amide hydrolase","volume":"91","author":"Palermo","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/ci200371z","article-title":"Approximating protein flexibility through dynamic pharmacophore models: Application to fatty acid amide hydrolase (FAAH)","volume":"51","author":"Bowman","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"12820","DOI":"10.1073\/pnas.0806121105","article-title":"Structure-guided inhibitor design for human FAAH by interspecies active site conversion","volume":"105","author":"Mileni","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-013-3161-2","article-title":"The effects of anandamide signaling enhanced by the FAAH inhibitor URB597 on coping styles in rats","volume":"230","author":"Haller","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2125.2011.04137.x","article-title":"Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects","volume":"73","author":"Li","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1124\/jpet.111.180257","article-title":"Mechanistic and pharmacological characterization of PF-04457845: A highly potent and selective fatty acid amide hydrolase Inhibitor that reduces inflammatory and noninflammatory pain","volume":"338","author":"Ahn","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-3-540-88955-7_11","article-title":"Targeting the Cannabinoid System to Produce Analgesia","volume":"Volume 1","author":"Sagar","year":"2009","journal-title":"Behavioral Neurobiology of the Endocannabinoid System"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/bjp.2008.335","article-title":"Inhibition of fatty acid amide hydrolase produces PPAR-\u03b1-mediated analgesia in a rat model of inflammatory pain","volume":"155","author":"Sagar","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.pain.2010.11.025","article-title":"Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis","volume":"152","author":"Schuelert","year":"2011","journal-title":"Pain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1213\/ANE.0000000000003563","article-title":"Inhibition of fatty acid amide hydrolase improves depressive-like behaviors independent of its peripheral antinociceptive effects in a rat model of neuropathic pain","volume":"129","author":"Jiang","year":"2019","journal-title":"Anesth. Analg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41386-020-00888-1","article-title":"The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: A double-blind, randomized, placebo-controlled proof-of-concept study","volume":"46","author":"Schmidt","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/13543784.2014.998335","article-title":"Discontinued anxiolytic drugs (2009\u20132014)","volume":"24","author":"Mandrioli","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40268-016-0127-y","article-title":"Safety, tolerability and pharmacokinetics of FAAH inhibitor V158866: A double-blind, randomised, placebo-controlled phase I study in healthy volunteers","volume":"16","author":"Pawsey","year":"2016","journal-title":"Drugs R&D"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bmcl.2018.11.048","article-title":"Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model","volume":"29","author":"Bhuniya","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJMoa1604221","article-title":"Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase","volume":"375","author":"Kerbrat","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mihai, D.P., Nitulescu, G.M., Ion, G.N.D., Ciotu, C.I., Chirita, C., and Negres, S. (2019). Computational drug repurposing algorithm targeting TRPA1 calcium channel as a potential therapeutic solution for multiple sclerosis. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11090446"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: Towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1021\/jm0608356","article-title":"Benchmarking sets for molecular docking","volume":"49","author":"Huang","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1021\/jm9602928","article-title":"The properties of known drugs. 1. Molecular frameworks","volume":"39","author":"Bemis","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1021\/jm050362n","article-title":"A critical assessment of docking programs and scoring functions","volume":"49","author":"Warren","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7379","DOI":"10.1073\/pnas.1016167108","article-title":"Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH)","volume":"108","author":"Min","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/157015906778019527","article-title":"Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes","volume":"4","author":"Manzanares","year":"2006","journal-title":"Curr. Neuropharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41401-018-0075-x","article-title":"Brain activity of anandamide: A rewarding bliss?","volume":"40","author":"Scherma","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1038\/tp.2014.53","article-title":"Central anandamide deficiency predicts stress-induced anxiety: Behavioral reversal through endocannabinoid augmentation","volume":"4","author":"Bluett","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/mds.28186","article-title":"High glucosylceramides and low anandamide contribute to sensory loss and pain in Parkinson\u2019s disease","volume":"35","author":"Valek","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lorca, M., Valdes, Y., Chung, H., Romero-Parra, J., Pessoa-Mahana, D., Mella, J., Parra, R., and Mahana, P. (2019). Three-dimensional quantitative structure-activity relationships (3D-QSAR) on a series of piperazine-carboxamides fatty acid amide hydrolase (FAAH) inhibitors as a useful tool for the design of new cannabinoid ligands. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102510"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejmech.2015.04.064","article-title":"Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH)","volume":"97","author":"Tabrizi","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Qiu, Y., Zhang, Y., Li, Y., and Ren, J. (2016). Discovery of uracil derivatives as potent inhibitors of fatty acid amide hydrolase. Molecules, 21.","DOI":"10.3390\/molecules21020229"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1021\/jm801042a","article-title":"Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors","volume":"52","author":"Wang","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zi\u0119ba, A., Laitinen, T., Patel, J., Poso, A., and Kaczor, A. (2021). Docking-based 3D-QSAR studies for 1,3,4-oxadiazol-2-one derivatives as FAAH inhibitors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116108"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1021\/ja110877y","article-title":"Fluoride-mediated capture of a noncovalent bound state of a reversible covalent enzyme inhibitor: X-ray crystallographic analysis of an exceptionally potent \u03b1-ketoheterocycle inhibitor of fatty acid amide hydrolase","volume":"133","author":"Mileni","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2016.03.010","article-title":"Involvement of opioid receptors in the systemic and peripheral antinociceptive actions of montelukast in the animal models of pain","volume":"779","author":"Ghorbanzadeh","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1213\/ANE.0000000000000174","article-title":"Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa B in a rat model of chronic constriction injury","volume":"118","author":"Zhou","year":"2014","journal-title":"Anesth. Analg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/OGX.0b013e31828baef9","article-title":"Update on raloxifene: Mechanism of action, clinical efficacy, adverse effects, and contraindications","volume":"68","author":"Gizzo","year":"2013","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00774-009-0155-6","article-title":"Analgesic effect of raloxifene on back and knee pain in postmenopausal women with osteoporosis and\/or osteoarthritis","volume":"28","author":"Fujita","year":"2010","journal-title":"J. Bone Miner. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1185\/030079906X154097","article-title":"Skeletal pain in postmenopausal women with osteoporosis: Prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration","volume":"22","author":"Scharla","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejim.2007.10.006","article-title":"Efficacy of raloxifene in treatment of fibromyalgia in menopausal women","volume":"19","author":"Sadreddini","year":"2008","journal-title":"Eur. J. Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17512433.2019.1587292","article-title":"Revefenacin for the treatment of chronic obstructive pulmonary disease","volume":"12","author":"Li","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1055\/s-0029-1212170","article-title":"Mechanism of action of a new class of insulin secretagogues","volume":"107","author":"Malaisse","year":"1999","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_60","first-page":"73","article-title":"Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines","volume":"2","author":"Rico","year":"2009","journal-title":"J. Asthma Allergy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1016\/j.cub.2017.01.037","article-title":"Nociception","volume":"27","author":"Tracey","year":"2017","journal-title":"Curr. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-540-33823-9_1","article-title":"Peripheral and central mechanisms of pain generation","volume":"177","author":"Schaible","year":"2007","journal-title":"Analgesia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/JPR.S26603","article-title":"Dorsal root ganglion\u2014A potential new therapeutic target for neuropathic pain","volume":"5","author":"Sapunar","year":"2012","journal-title":"J. Pain Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Thompson, J.M., Blanton, H.L., Pietrzak, A., Little, W., Sherfey, C., and Guindon, J. (2019). Front and hind paw differential analgesic effects of amitriptyline, gabapentin, ibuprofen, and URB937 on mechanical and cold sensitivity in cisplatin-induced neuropathy. Mol. Pain, 15.","DOI":"10.1177\/1744806919874192"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1177\/0333102414566862","article-title":"Effects of peripheral FAAH blockade on NTG-induced hyperalgesia-evaluation of URB937 in an animal model of migraine","volume":"35","author":"Greco","year":"2015","journal-title":"Cephalalgia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.pbb.2011.06.022","article-title":"Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice","volume":"99","author":"Kinsey","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.chroma.2015.10.093","article-title":"Quantitation of repaglinide and metabolites in mouse whole-body thin tissue sections using droplet-based liquid microjunction surface sampling-high-performance liquid chromatography-electrospray ionization tandem mass spectrometry","volume":"1439","author":"Chen","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41419-018-0783-7","article-title":"The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain","volume":"9","author":"Eriksson","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-387667-6.00001-4","article-title":"Buclizine","volume":"36","author":"Mostafa","year":"2011","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Veenman, L. (2020). Raloxifene as treatment for various types of brain injuries and neurodegenerative diseases: A good start. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207586"},{"key":"ref_71","first-page":"1","article-title":"Open Babel: An open chemical toolbox","volume":"3","author":"Banck","year":"2011","journal-title":"J. Cheminfo."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/jcc.21707","article-title":"PaDEL-descriptor: An open-source software to calculate molecular descriptors and fingerprints","volume":"32","author":"Yap","year":"2011","journal-title":"J. Comput. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Land, H., and Humble, M.S. (2017). YASARA: A Tool to Obtain Structural Guidance in Biocatalytic Investigations. Protein Engineering, Humana Press.","DOI":"10.1007\/978-1-4939-7366-8_4"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jmb.2010.05.034","article-title":"Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: Discovery of a deacylating water molecule and insight into enzyme inactivation","volume":"400","author":"Mileni","year":"2010","journal-title":"J. Mol. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1021\/ja308733u","article-title":"A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase","volume":"135","author":"Bertolacci","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1021\/acs.jctc.8b00672","article-title":"Predicting the binding of fatty acid amide hydrolase inhibitors by free energy perturbation","volume":"14","author":"Saha","year":"2018","journal-title":"J. Chem. Theory Comput."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Krieger, E., Dunbrack, R.L., Hooft, R.W.W., and Krieger, B. (2011). Assignment of protonation states in proteins and ligands: Combining pKa prediction with hydrogen bonding network optimization. Computational Drug Discovery and Design, Springer.","DOI":"10.1007\/978-1-61779-465-0_25"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jcc.10128","article-title":"Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation","volume":"23","author":"Jakalian","year":"2002","journal-title":"J. Comput. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/prot.21123","article-title":"Comparison of multiple Amber force fields and development of improved protein backbone parameters","volume":"65","author":"Hornak","year":"2006","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/ct049941i","article-title":"An efficient linear-scaling Ewald method for long-range electrostatic interactions in combined QM\/MM calculations","volume":"1","author":"Nam","year":"2004","journal-title":"J. Chem. Theory Comput."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jcc.23899","article-title":"New ways to boost molecular dynamics simulations","volume":"36","author":"Krieger","year":"2015","journal-title":"J. Comput. Chem."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/1\/38\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:54:38Z","timestamp":1760169278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/1\/38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ph15010038"],"URL":"https:\/\/doi.org\/10.3390\/ph15010038","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}